UNSPSC 51143401: Acetaminophen/caffeine/isometheptene

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN105. This VA Drug Class (CN105) classifies this compound as belonging to the group ANTIMIGRAINE AGENTS.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51143401 Acetaminophen/caffeine/isometheptene is a Commodity code that in practice encompasses a wider range of pharmaceutical products and over-the-counter medications than its narrow code name suggests. State and local governments procure generic pharmaceuticals, naloxone, OTC products, and related pharmaceutical supplies through this code to support public health programs, emergency response, and employee health benefit programs. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. The Seminole County, Florida procurement (IFB 60459723LAS, due July 26, 2023) solicited 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to support community health initiatives. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements, signaling state interest in alternative pharmaceutical supply chains.

Recent activity concentrates in the South and upper Midwest. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and OTC products across participating state and local facilities in Minnesota and Oregon. That procurement requires vendors to work through three authorized wholesalers, comply with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, maintain $5 million commercial general liability coverage, and accept a 3 percent administrative fee on all contract purchases. Awards under MMCAP's RFP take effect July 1, 2026, with a two-year initial term and optional extensions. Vendors responding to pharmaceutical procurements at this tier face increasing emphasis on direct wholesaler relationships, EDI capability, pricing transparency in multiple formats (flat price, net price, WAC-minus), and compliance with federal drug-supply regulations and FDA requirements.